Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-120 or AG-221 with Induction and Consolidation Therapy in Newly Diagnosed AML with IDH1/2 Mutation
NCT02632708Phase 1Active, not recruiting
- Sponsor
- Servier
- Start
- Dec 2015
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of ivosidenib and enasidenib in acute myeloid leukemia (AML) (6 arms), sponsored by Servier. Primary endpoint: Percentage of Participants with Adverse Events at 26 weeks. Started Dec 2015; status: active, not recruiting.
02
Drugs
ivosidenibenasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02632708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632708.